SCHEMBL25577008

SCHEMBL25577008

CCOC(=O)[C@H](C)Cc1cc(C(F)(F)F)nn1C(C)C

nearest known ligand 0.42

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
MLYCD O95822 1/20 0.42
EPHX2 P34913 1/20 0.36
PPARG P37231 1/20 0.36
ALOX5 P09917 1/20 0.36
PTGS1 P23219 1/20 0.36
ALDH1A1 P00352 4/20 0.36
HPGD P15428 3/20 0.36
MEN1 O00255 2/20 0.36
KMT2A Q03164 2/20 0.36
MAPT P10636 1/20 0.36
LMNA P02545 3/20 0.36
POLB P06746 1/20 0.34
KDM4E B2RXH2 2/20 0.34
TP53 P04637 1/20 0.34
L3MBTL1 Q9Y468 1/20 0.34
GAA P10253 2/20 0.33
TGFBR1 P36897 1/20 0.32
NPSR1 Q6W5P4 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25240747 1.00 MLYCD (0.42) MLYCDEPHX2PPARGALOX5PTGS1
SCHEMBL25577006 1.00 MLYCD (0.42) MLYCDEPHX2PPARGALOX5PTGS1
SCHEMBL25267624 0.84 MLYCD (0.38) MLYCDMEN1KMT2ALMNAPOLB
SCHEMBL25211507 0.84 MLYCD (0.38) MLYCDMEN1KMT2ALMNAPOLB
SCHEMBL25212749 0.84 MLYCD (0.38) MLYCDMEN1KMT2ALMNAPOLB
SCHEMBL15724389 0.77 TGFBR1 (0.33) ALOX5PTGS1LMNAKDM4EGAA
SCHEMBL15484740 0.76 LMNA (0.44) ALOX5PTGS1ALDH1A1HPGDMEN1
SCHEMBL12871859 0.76 PTGS1 (0.34) PTGS1LMNAKDM4ETGFBR1
SCHEMBL25238172 0.75 TGFBR1 (0.33) GAATGFBR1
SCHEMBL25214379 0.75 TGFBR1 (0.33) GAATGFBR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240400579-A1 SPIROCYCLIC MODULATORS OF CHOLESTEROL BIOSYNTHESIS AND THEIR USE FOR PROMOTING REMYELINATION GENENTECH, INC. 2024-12-05 US disclosed
EP-4436976-A1 SPIROCYCLIC MODULATORS OF CHOLESTEROL BIOSYNTHESIS AND THEIR USE FOR PROMOTING REMYELINATION Genentech, Inc. (US) 2024-10-02 EP disclosed
CN-118510783-A Spiro modulators of cholesterol biosynthesis and their use for promoting remyelination 基因泰克公司 2024-08-16 CN disclosed
WO-2023097234-A1 SPIROCYCLIC MODULATORS OF CHOLESTEROL BIOSYNTHESIS AND THEIR USE FOR PROMOTING REMYELINATION GENENTECH, INC. (US) 2023-06-01 WO disclosed
WO-2023097234-A1 SPIROCYCLIC MODULATORS OF CHOLESTEROL BIOSYNTHESIS AND THEIR USE FOR PROMOTING REMYELINATION GENENTECH, INC. (US) 2023-06-01 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240400579-A1 SPIROCYCLIC MODULATORS OF CHOLESTEROL BIOSYNTHESIS AND THEIR USE FOR PROMOTING REMYELINATION MAG, NR1H2, PMP22 MLYCD 731/4885EPHX2 1123/4885PPARG 453/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.